IL4 as A Potential Drug Target Or Biomarker for Various Diseases

Target Name: IL4

NCBI ID: G3565

Content of Review Report on IL4 Target / Biomarker

IL4

IL4 as A Potential Drug Target Or Biomarker for Various Diseases

IL4 (Binetrakin) is a protein that is expressed in the T-cells, a type of white blood cell that plays a crucial role in the immune system. The T-cells are responsible for recognizing and responding to foreign substances in the body, and IL4 is involved in this process. In recent years, researchers have been interested in IL4 as a potential drug target or biomarker because of its involvement in various diseases, including autoimmune disorders, allergies, and cancer.

IL4 is a member of the immunoglobulin family, which includes proteins such as antibodies that are responsible for recognizing and neutralizing foreign substances in the body. In IL4, the constant region of the protein contains a unique domain that is involved in the interaction with other proteins, including the B cell maturation antigen (BCMA) and the T-cell receptor alpha chain (TCR伪). This domain is known as the B-cell maturation antigen (BCMA) interface, and it is thought to play a role in the regulation of T-cell development and function.

IL4 has been shown to be involved in the development and progression of various diseases, including autoimmune disorders, allergies, and cancer. For example, studies have shown that IL4 is involved in the development of multiple sclerosis (MS), an autoimmune disorder that affects the central nervous system. In these studies, IL4 has been shown to promote the growth and survival of immune cells that are involved in the development of MS, including T-cells.

In addition to its involvement in autoimmune disorders, IL4 has also been shown to be involved in the development of allergies. Allergies are conditions in which the body's immune system becomes hypersensitive to a particular substance, leading to the production of antibodies that cause symptoms such as itching, swelling, and sneezing. IL4 has been shown to play a role in the development of allergies by promoting the production of antibodies that are involved in immune responses.

Finally, IL4 has also been shown to be involved in the development and progression of certain types of cancer. For example, studies have shown that IL4 is involved in the development of hormone-sensitive breast cancer, as well as in the growth and survival of other types of cancer cells.

Despite these promising findings, the use of IL4 as a drug target or biomarker is still in its early stages. While there are several compounds that have been shown to interact with IL4 and have the potential to be used as treatments for various diseases, more research is needed to fully understand the role of IL4 in these processes.

One of the challenges in studying IL4 is its complex structure. IL4 is a protein that contains multiple domains, including the BCMA interface, and it is not clear how these domains work together to promote the function of the protein. Additionally, the regulation of IL4 by various signaling pathways is not well understood.

Despite these challenges, researchers are making progress in the study of IL4. Several studies have shown that the BCMA interface plays a critical role in the regulation of IL4 function, and that changes in this interface can have a significant impact on the function of the protein. For example, studies have shown that the addition of a specific amino acid at the BCMA interface can significantly alter the activity of IL4, and that this effect is dependent on the specific type of amino acid.

In addition to its role in the BCMA interface, IL4 is also thought to be involved in the regulation of its own function by several other signaling pathways. For example, studies have shown that IL4 is involved in the regulation of cell survival and that changes in this process can have a significant impact on the function of the protein. Additionally, IL4 is thought to be involved in the regulation of inflammation, and changes in this process can

Protein Name: Interleukin 4

Functions: Cytokine secreted primarily by mast cells, T-cells, eosinophils, and basophils that plays a role in regulating antibody production, hematopoiesis and inflammation, and the development of effector T-cell responses (PubMed:3016727, PubMed:1993171). Induces the expression of class II MHC molecules on resting B-cells. Enhances both secretion and cell surface expression of IgE and IgG1 (PubMed:1993171). Regulates also the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes (PubMed:2521231). Positively regulates IL31RA expression in macrophages. Stimulates autophagy in dendritic cells by interfering with mTORC1 signaling and through the induction of RUFY4. In addition, plays a critical role in higher functions of the normal brain, such as memory and learning (By similarity). Upon binding to IL4, IL4R receptor dimerizes either with the common IL2R gamma chain/IL2RG to produce the type 1 signaling complex, located mainly on hematopoietic cells, or with the IL13RA1 to produce the type 2 complex, which is expressed also on nonhematopoietic cells (PubMed:10219247, PubMed:11526337, PubMed:18243101). Engagement of both types of receptors initiates JAK3 and to a lower extend JAK1 phosphorylation leading to activation of the signal transducer and activator of transcription 6/STAT6 (PubMed:7721895)

The "IL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets